Navigation Links
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome

f this syndrome, there are no treatments specifically approved for FMS in the United States or elsewhere and the addressable patient population is not yet well established. For more information about fibromyalgia, visit http://www.fmsresource.com.

About Cypress

Cypress is committed to be the innovator and leader in providing products that improve the treatment of Functional Somatic Syndromes and other central nervous system conditions, including fibromyalgia syndrome. Cypress' strategy involves acquiring/in-licensing undervalued central nervous system active compounds and developing them for new indications.

For more information about Cypress, please visit Cypress' web site at www.cypressbio.com.

This press release, as well as Cypress' SEC filings and web site at http://www.cypressbio.com, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including statements about the potential of milnacipran to treat Fibromyalgia Syndrome and our planned NDA filing for milnacipran. Actual results could vary materially from those described as a result of a number of factors, including those set forth in Cypress Annual Report on Form 10-K, the most recent Quarterly Report on Form 10-Q and any subsequent SEC filings and including, but not limited to, that more detailed analysis of the trial results may not be favorable or may lead to different conclusions; the FDA may not accept our first Phase III clinical trial as one of the two pivotal trials required for NDA approval, that upon further reflection that we may determine not to submit an NDA in 2007, that we may not be able to protect our milnacipran patent portfolio and that milnacipran may never be approved as a drug by the FDA.

About Forest Laboratories and Its Pro
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
2. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
6. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:12/19/2014)... 19, 2014 Breckenridge Pharmaceutical, Inc. announced today ... MSN Laboratories Pvt. Ltd. ( Hyderabad, India ... several new ANDAs.  Under the terms of the agreement, ... to Breckenridge for the U.S. market, and Breckenridge will ... and MSN have agreed to develop an oral antibiotic ...
(Date:12/19/2014)...  Monarch America Inc. (OTCQB: CANK) ("Monarch America" or ... provide this review of the Company,s recent achievements and ... "Over this past year, we achieved many of our ... to say that Monarch America is in a stronger ... been," stated Eric Hagen , CEO of Monarch ...
(Date:12/19/2014)... 2014 Research and Markets ( ... "Micro Market Monitor: North American Dermatology Diagnostic ... http://photos.prnewswire.com/prnh/20130307/600769 ... which has resulted in fueling the overall demand ... purpose of these dermatology devices is to assist ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3
... Feb. 17 Northwest,Biotherapeutics, Inc. (OTC Bulletin Board: ... today announced further long-term follow-up data, for the,second ... and Phase I/II clinical trials,with DCVax(R)-Brain in patients ... of brain cancer. During the update period from ...
... of eleven wounds healed in 6 weeks or lessPRINCETON, ... (OTC Bulletin Board: DSCI ), a provider of ... Dressings were the focus of a case series on ... previously failed to heal while being managed with such ...
Cached Medicine Technology:Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival 2Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival 3Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival 4Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival 5MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series 2MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series 3
(Date:12/20/2014)... An improving macroeconomic landscape and a growing ... Massage Services industry over the five years to ... anticipated 1.0% annualized increase in per capita disposable income ... means to afford additional massages. “While the share of ... given year has declined from 2009 to 2012, this ...
(Date:12/20/2014)... December 20, 2014 The print component ... with a distribution of approximately 160,000 copies and an ... nationally through a vast social media strategy and across ... To explore the digital version of the campaign, ... exclusive interview with the ladies of CTV’s The Social. ...
(Date:12/20/2014)... 2014 The Doctor’s Office Urgent Care of ... part of a decade. They’ve treated over 40,000 patients ... healthcare alternative to the Paramus area. , ... additions to their staff of top-notch board certified physicians: Christine ... These new doctors will work tirelessly to carry ...
(Date:12/20/2014)... Francisco, CA (PRWEB) December 20, 2014 ... Social Innovation company just launched first birthday focused portal ... services, “MERRY BIRTHDAY MESSAGE” launched in both US and ... MERRY BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , MERRY ... for everyone’s birthday around the world. , Features, Choose ...
(Date:12/20/2014)... Developers of FCPX 3rd ... plugin for Final Cut Pro X entitled TranSlice Volume ... allows users to create hand drawn text animations without ... CEO of Pixel Film Studios. “TranSlice Volume 5 was ... an easy to use interface.” , TranSlice Volume 5 ...
Breaking Medicine News(10 mins):Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... , CHICAGO, Aug. 14 International Components ... manufacturing portable rechargeable systems, today launched a new series ... range of electronic devices. Marketed under the Elpac Power ... the company,s rapidly expanding portfolio of high-efficiency power supplies ...
... KENILWORTH, N.J., Aug. 14 Schering-Plough Corporation (NYSE: ... Drug Administration (FDA) has approved SAPHRIS((R)) (asenapine) sublingual tablets for ... manic or mixed episodes associated with bipolar I disorder with ... as a first-line treatment and is the first psychotropic drug ...
... , , , ... OXBO) today announced that the company has received approval to begin ... of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the Company,s ... approval from Swissmedic means that we can begin enrolling patients," said ...
... , ... Web-based admissions software for long-term care will present a technology and admissions educational session ... ... of automated Web-based admissions for long-term care providers, announced today that it will present ...
... ... 40% of women find holidays more stressful than they should be. A male,s ... is their biggest nightmare. Under 30s are the most stressed on holiday. , ... Cardiff, UK (PRWEB) August 14, 2009 ...
... raise or lower clot risk , THURSDAY, Aug. 13 ... pill influences her risk of developing blood clots of ... have long known that oral contraceptives, which contain the ... deep vein thrombosis of the leg and pulmonary embolism, ...
Cached Medicine News:Health News:Elpac Power System Extends Energy Star Portfolio with 65-Watt External Power Supply 2Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 2Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 3Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 4Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 5Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 6Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 7Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 8Health News:Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland 2Health News:Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland 3Health News:Patient Placement Systems Presents a Session at the THCA 2009 Annual Convention 2Health News:Patient Placement Systems Presents a Session at the THCA 2009 Annual Convention 3Health News:Spain Has The 'Stress' Factor, According to Confused.com 2Health News:Spain Has The 'Stress' Factor, According to Confused.com 3Health News:Some Birth Control Pills Safer Than Others 2Health News:Some Birth Control Pills Safer Than Others 3
... The Evans AFO is designed to ... disorders associated with immobility such as hip ... at the calcaneus. A comfortable Kodel lining ... patient. The anti-rotation bar is easily ...
Provides secure fracture immobilization while allowing for full range of motion at shoulder and elbow...
... MPO® by RCAI provides adjustable static stretch ... conditions such as diminished foot and ankle ... rotation. Medial/lateral straps attached to the sides ... ankle to be controlled, as needed, in ...
... features a completely padded posterior shell ... to provide passive flexion to help ... or Achilles tendonitis. Its neutral ... left or right. A foam ...
Medicine Products: